Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells

AUTOR(ES)

Bachrach, Estanislao

FONTE

National Academy of Sciences

RESUMO

Cell-based therapy for Duchenne muscular dystrophy patients and mdx mice has proven to be a safe but ineffective form of treatment. Recently, a group of cells called muscle side population (SP) cells have been isolated based on their ability to efflux the DNA-binding dye Hoechst. To understand the potential of skeletal muscle SP cells to serve as precursors for muscle, SP cells from the two mice strains mdx5cv and C57BL/6N were isolated, transduced, and transplanted. Under coculture conditions with myogenic cells, some cells within the SP cell population can give rise to early Pax7-positive satellite cells and other later stage myogenic cells. Transduced SP cells were transplanted via the tail vein and were shown to successfully deliver enhanced GFP and human microdystrophin to the skeletal muscle of nonirradiated mdx5cv mice, thus demonstrating their ability to travel through the capillaries and enter into damaged muscle. These results demonstrate that i.v. delivery of genes via SP cells is possible and that these SP cells are capable of recapitulating the myogenic lineage. Because this approach shows definitive engraftment by using autologous transplantation of noninjured recipients, our data may have substantial implications for therapy of muscular dystrophy.

Documentos Relacionados

• Mechanical properties of dystrophic mouse muscle
• Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein
• Molecular characterization of mouse gastric epithelial progenitor cells
• Production of interleukin 1beta by human hematopoietic progenitor cells.
• Human circulating AC133+ stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle